and Recent Developments We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. We currently have two product candidates in clinical development, LTI-03 and LTI-01, however, due to insufficient funding we have paused development of LTI 01 for …
Negative free cash flow of -$19M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$50M
▲ +20.7% YoY
Op. Margin
—
ROIC
-124.41%
▲ +55.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$17M
▲ +13.1% YoY
Op. Cash Flow (TTM)
-$17M
▲ +13.1% YoY
Net Debt
$478K
Cash & Equiv.
$4M
Continue Research